Immunology | Phase I/ Phase II Developments

Annexon Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics

Lead Product(s): ANX005

Therapeutic Area: Immunology Product Name: ANX005

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Redmile Group

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Financing July 01, 2020

Details:

This financing is intended to advance multiple product candidates in Annexon’s portfolio, including ANX005 and ANX007.

Kezar Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kezar Provides Data Update from MISSION Study of KZR-616

Lead Product(s): KZR-616

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

Overall, improvements were seen across 7 measures of disease activity, and 2 of 2 patients with lupus nephritis experienced a greater than 50% reduction in proteinuria. A positive safety and tolerability profile was observed with step-up dosing of KZR-616.

Alpine Immune Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

Lead Product(s): ALPN-101

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

The posters are going to cover Study of ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist.

Kezar Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kezar Provides Statement Regarding COVID-19 Pandemic

Lead Product(s): KZR-616

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 09, 2020

Details:

Kezar anticipate delays in their previously anticipated clinical development and data release milestones for KZR-616. However, Phase 1b portion of their MISSION study will continue to receive data.

Equillium

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versu...

Lead Product(s): Itolizumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

The research, conducted in mouse models, demonstrates that blockade of the CD6-ALCAM pathway with anti-CD6 antibodies reduces incidence and severity of both GVHD and gastro-intestinal inflammation.

Sorrento Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences

Lead Product(s): Resiniferatoxin

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts.

Find

Find Immunology Drugs in Phase I/II Clinical Development

Phase I/ Phase II

Product Type

Companies

Annexon Biosciences

Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics

Kezar Life Sciences

Kezar Provides Data Update from MISSION Study of KZR-616

Alpine Immune Sciences

Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

Kezar Life Sciences

Kezar Provides Statement Regarding COVID-19 Pandemic

Equillium

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versu...

Sorrento Therapeutics

Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences